background
acut
respiratori
distress
syndrom
ard
associ
high
mortal
rate
ard
patient
suffer
sever
hypoxemia
extracorpor
membran
oxygen
ecmo
therapi
may
necessari
ensur
oxygen
ard
variou
etiolog
includ
trauma
ischemiareperfus
injuri
infect
variou
origin
associ
immunolog
respons
may
vari
support
immunolog
respons
patient
collect
use
intraven
igm
immunoglobulin
therapi
enhanc
likelihood
pulmonari
recoveri
method
ard
patient
admit
intens
care
unit
icu
place
ecmo
treat
ivig
group
n
without
control
group
n
intraven
igmenrich
immunoglobulin
day
initi
stage
ard
analyz
retrospect
result
baselin
characterist
differ
group
although
ivig
group
show
significantli
reduc
oxygen
index
compar
control
group
found
differ
length
icu
stay
ventil
paramet
find
signific
differ
group
extent
inflamm
overal
surviv
conclud
administr
igmenrich
immunoglobulin
addit
therapi
benefici
effect
patient
sever
ard
requir
ecmo
support
trial
registr
clinic
trial
retrospect
regist
acut
respiratori
distress
syndrom
ard
character
pulmonari
inflamm
caus
pulmonari
extrapulmonari
origin
sepsi
bacteri
pneumonia
polytrauma
aspir
pneumonia
common
caus
ard
predictor
surviv
includ
age
type
underli
medic
condit
sever
pulmonari
injuri
presenc
extrapulmonari
organ
dysfunct
ongo
sepsi
current
clinic
attempt
rescu
ard
patient
includ
individu
ventil
fluid
manag
adequ
infect
control
includ
earli
applic
broadspectrum
antiinfect
neuromuscular
blockad
use
cisatracurium
sedat
strategi
prone
posit
final
extracorpor
membran
oxygen
ecmo
ensur
oxygen
although
incid
ard
rel
high
five
eight
case
per
european
inhabit
even
usa
variou
pathomechan
partial
understood
result
differ
experiment
approach
understand
immun
respons
earli
ard
one
welldescrib
issu
decreas
immunoglobulin
level
patient
sever
infect
element
immunolog
respons
initi
phase
inflamm
respons
sepsi
therefor
one
approach
support
critic
ill
patient
intraven
administr
igmenrich
immunoglobulin
sinc
could
potenti
decreas
sever
inflamm
although
treatment
omit
recent
sepsi
guidelin
due
lack
support
evid
highqual
trial
sever
studi
includ
one
metaanalysi
describ
benefici
effect
immunoglobulin
acut
pneumonia
induc
drugresist
bacteri
infect
furthermor
sever
case
report
describ
benefici
effect
antivir
therapi
combin
intraven
immunoglobulin
therapi
immunecompromis
patient
base
data
treat
patient
ard
requir
ecmo
therapi
igmenrich
immunoglobulin
immedi
intens
care
unit
icu
admiss
object
studi
investig
whether
intraven
immunoglobulin
administr
could
improv
clinic
cours
ard
patient
treat
ecmo
therefor
mortal
durat
ecmo
therapi
incid
renal
replac
therapi
durat
vasopressor
antiinfect
therapi
length
stay
icu
length
stay
hospit
analyz
retrospect
ard
patient
requir
ecmo
therapi
studi
approv
local
research
ethic
committe
univers
hospit
eberhardkarl
univers
germani
patient
sever
ard
treat
ecmo
therapi
januari
januari
institut
analyz
retrospect
patient
ecmo
therapi
requir
due
hypoxia
andor
increas
pulmonari
resist
preclud
protect
lung
ventil
ecmo
therapi
perform
accord
guidelin
extracorpor
life
support
organ
elso
use
ilaact
system
novalung
stolberg
germani
fiftyseven
patient
analyz
twentyeight
patient
treat
igmenrich
immunoglobulin
biotest
dreieich
germani
ivicgroup
pentaglobin
igmenrich
polyval
immunoglobulin
prepar
deriv
plasma
pool
contain
mg
igm
mg
iga
mg
igg
per
millilitr
indic
igmenrich
immunoglobulin
ivig
treatment
determin
discret
treat
intensivist
ivig
appli
viral
infect
infect
due
multiresist
gramneg
bacteria
mrgn
suspect
ivig
dose
perform
accord
instruct
manufactur
mlkgh
ml
initi
dose
follow
mlkgh
h
total
dose
mgkg
achiev
twentynin
patient
receiv
immunoglobulin
control
group
vasopressor
norepinephrin
sanofiaventi
germani
use
volum
resuscit
accord
sepsi
guidelin
renal
replac
therapi
perform
citrat
anticoagul
multifiltr
freseniu
medic
care
bad
homburg
vdh
germani
patient
acut
renal
failur
data
retrospect
extract
ardsspecif
databas
institut
sinc
electron
patient
manag
system
chang
time
frame
requir
data
avail
ard
patient
mrsa
vre
screen
perform
routin
patient
admit
icu
identifi
causal
infect
bronchoalveolar
lavag
bal
sampl
blood
cultur
urinari
sampl
periop
sampl
analyz
patient
risk
pcr
atyp
pathogen
also
perform
bal
sampl
infect
defin
colonyform
unit
cfu
bal
andor
urinari
cultur
blood
cultur
replic
bacteri
growth
defin
infect
flu
season
influenza
infect
detect
pcr
bal
sampl
also
analyz
viral
pathogen
cytomegaloviru
cmv
herp
simplex
viru
hsv
posit
find
virus
confirm
cell
cultur
patient
unknown
pathogen
immun
suppress
addit
screen
pathogen
antiinfect
therapi
appli
accord
local
guidelin
consid
local
resist
pattern
categor
data
report
number
percentag
continu
data
summar
median
rang
ie
minimum
maximum
valu
unless
otherwis
indic
compar
categor
variabl
outcom
occurr
infect
inhospit
death
ivig
group
n
patient
control
group
includ
patient
receiv
ivig
therapi
chisquar
test
use
intergroup
comparison
continu
data
twotail
twosampl
test
gener
perform
origin
data
exhibit
lognorm
distribut
eg
icu
length
stay
lo
raw
data
logtransform
prior
analysi
test
p
valu
assum
indic
statist
signific
differ
group
data
analysi
perform
use
statist
softwar
sa
institut
inc
cari
nc
usa
total
patient
ard
requir
ecmo
therapi
analyz
retrospect
twentyeight
patient
treat
igmenrich
immunoglobulin
ivig
day
accord
manufactur
instruct
ivig
group
patient
receiv
ivig
therapi
control
group
advers
event
report
ivig
applic
median
age
group
year
rang
year
control
group
year
ivig
group
median
simplifi
acut
physiolog
score
sap
acut
physiolog
chronic
health
evalu
apach
score
compar
group
tabl
median
apach
score
ivig
group
vs
control
group
ivigtr
patient
control
patient
apach
score
equal
greater
regard
preexist
diseas
diabet
mellitu
cardiac
diseas
immun
suppress
malign
common
ivig
group
tabl
five
patient
control
group
suffer
ard
extrapulmonari
origin
three
patient
pancreat
two
polytrauma
initi
pao
fio
ratio
ivig
group
significantli
lower
control
group
ivig
median
vs
control
test
logtransform
data
p
seventyf
percent
ivigtr
patient
sever
ard
moder
ard
patient
show
mild
ard
control
group
patient
sever
ard
moder
ard
mild
ard
ecmo
durat
shorter
control
group
day
median
day
compar
ivig
group
day
median
day
could
reduc
earlier
control
group
median
day
ivig
group
median
day
durat
ventil
support
longer
ivig
group
h
median
h
compar
control
group
h
median
h
test
logtransform
data
p
five
patient
control
group
three
patient
ivig
group
extub
ecmo
discontinu
ten
patient
control
group
seven
patient
ivig
group
suffer
anemia
due
bleed
complic
includ
cerebr
hemorrhag
control
n
ivig
n
tabl
patient
suffer
septic
shock
requir
vasopressor
therapi
control
day
vs
ivig
day
renal
replac
therapi
often
requir
control
group
vs
p
pearson
chisquar
test
hepatobiliari
dysfunct
compar
group
control
ivig
control
patient
ivigtr
patient
one
pathogen
could
identifi
caus
pulmonari
inflamm
patient
control
group
bacteri
pathogen
legionella
n
streptococcu
pneumonia
n
pneumocysti
jirovecii
n
e
coli
n
identifi
bal
sampl
none
control
patient
show
multidrugresist
bacteria
sampl
control
patient
viral
pathogen
detect
bal
sampl
influenza
n
herp
viru
n
herp
viru
infect
includ
hsv
n
cmv
n
herp
viral
infect
confirm
cellbas
cultur
five
control
patient
fungal
infect
diagnos
via
blood
cultur
n
abdomin
sampl
n
bal
aspergillu
n
nine
control
patient
causal
pathogen
could
identifi
two
ivig
patient
infect
resist
bacteria
stenotrophomona
maltophilia
mrsa
ivig
patient
bacteri
pathogen
legionella
n
streptococcu
pneumonia
n
pneumocysti
jirovecii
n
mycoplasma
n
identifi
bal
sampl
viral
infect
frequent
ivig
group
p
pearson
chisquar
test
especi
influenza
infect
p
half
ivig
patient
viral
pneumonia
diagnos
accord
result
bal
sampl
radiolog
find
clinic
symptom
one
follow
virus
could
detect
bal
sampl
influenza
n
herp
viru
n
herp
viru
infect
includ
hsv
n
cmv
n
bal
blood
n
ivigtr
patient
fungal
infect
diagnos
urinari
tract
n
abdomin
sampl
n
addit
one
patient
suffer
aspergillosi
pneumonia
three
ivigpati
causal
pathogen
could
identifi
durat
antiinfect
treatment
significantli
longer
ivig
group
control
group
control
median
day
day
ivig
median
day
day
test
logtransform
data
p
six
patient
control
group
four
patient
ivig
group
underw
antiinfect
treatment
admiss
icu
exclud
patient
durat
antiinfect
therapi
rel
lo
icu
significantli
differ
group
control
median
fraction
lo
icu
ivig
lo
icu
patient
treat
ivig
stay
median
day
icu
day
day
fig
fortythre
percent
patient
die
three
patient
die
within
first
week
due
cerebr
hemorrhag
n
multiorgan
failur
due
septic
shock
n
control
patient
spent
median
day
icu
day
day
hospit
day
patient
die
five
patient
die
within
first
week
due
cerebr
hemorrhag
heart
failur
subarachnoid
bleed
polytrauma
hypox
brain
injuri
h
admiss
other
die
multiorgan
failur
due
acut
pancreat
lymphocyt
level
analyz
retrospect
avail
initi
admiss
lymphocyt
level
differ
group
control
aliv
control
dead
ivig
aliv
ivig
dead
howev
lymphocyt
level
higher
survivor
compar
nonsurvivor
fig
increas
lymphocyt
promin
survivor
compar
nonsurvivor
control
aliv
ivig
aliv
control
dead
ivig
dead
fig
addit
patient
treat
ivig
increas
treatment
promin
control
group
first
day
fig
sinc
evalu
differenti
blood
count
routin
limit
data
avail
determin
signific
differ
purpos
analysi
systemat
investig
potenti
effect
igmenrich
immunoglobulin
outcom
ard
patient
requir
ecmo
therapi
analyz
patient
patient
treat
igmenrich
ivig
patient
receiv
ivig
therapi
patient
suffer
septic
shock
ivigtr
patient
control
patient
sever
ard
variou
origin
howev
although
ivig
group
lower
pao
fio
ratio
requir
longer
ventil
support
longer
vasopressor
therapi
longer
antiinfect
therapi
includ
mrgninfect
patient
outcom
paramet
lo
icu
lo
hospit
mortal
significantli
differ
group
sever
studi
hypogammaglobulinemia
overexpress
gene
encod
immunoglobulin
segment
identifi
patient
septic
shock
therefor
ivig
treatment
could
logic
requir
patient
includ
ivig
therapi
ard
patient
base
consider
although
measur
immunoglobulin
level
treatment
inde
recent
retrospect
analysi
patient
high
igg
level
associ
high
mortal
sepsi
patient
pcr
analysi
show
earli
molecular
respons
igm
blood
patient
sepsi
igm
level
remain
low
nonsurviv
sepsi
patient
wherea
igm
level
increas
transient
surviv
patient
singl
studi
metaanalys
shown
benefici
effect
ivig
therapi
patient
sepsi
howev
ivig
treatment
remain
controversi
random
studi
shown
benefici
effect
intervent
patient
sepsi
sepsisassoci
condit
therefor
ivig
therapi
current
recommend
latest
sepsi
guidelin
immunoglobulin
interact
tlymphocyt
bacteri
erad
sever
sepsi
b
cell
deplet
due
apoptosi
sinc
analysi
retrospect
could
measur
hladr
express
cytokin
profil
patient
howev
found
trend
increas
lymphocyt
nonsurvivor
compar
survivor
may
reflect
see
benefici
effect
ivig
therapi
although
immunoglobulin
may
play
import
role
innat
immun
respons
ard
nonspecif
immunoglobulin
may
effect
lymphopenia
environ
lymphopenia
describ
ard
patient
anim
model
viral
infect
mycoplasma
infect
affect
lymphoid
tissu
howev
small
group
whether
variabl
respons
due
genet
alter
immun
evas
bacteria
differ
stage
sepsi
unknown
studi
limit
retrospect
analysi
limit
number
ard
patient
sinc
chang
ecmo
system
studi
period
includ
patient
treat
one
system
exclud
impact
system
differ
furthermor
sinc
ivig
order
physician
primarili
viral
infect
mrgn
infect
suspect
ivig
group
includ
patient
infect
howev
may
reflect
true
clinic
circumst
caus
diseas
typic
determin
admiss
ard
multifactori
diseas
heterogen
pathogenesi
variabl
time
clinic
present
therefor
one
specif
therapi
unlik
improv
outcom
rather
exclud
singl
therapeut
option
identifi
patient
risk
factor
individu
ard
stage
may
import
success
outcom
report
retrospect
analysi
intraven
igm
administr
initi
stage
sever
ard
improv
overal
outcom
sever
diseas
